
CYTO
Healthcare · Biotechnology · $1.1M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 30, 2022 | Before the open | 0.00 | 0.00 | — |
| Aug 18, 2022 | Time not confirmed | — | 0.00 | — |
| Apr 12, 2022 | Time not confirmed | — | -1.31 | — |
| Nov 18, 2021 | Time not confirmed | — | 0.00 | — |
| Sep 8, 2021 | Time not confirmed | — | 0.00 | — |
| May 18, 2021 | Time not confirmed | — | -0.29 | — |
| Mar 31, 2021 | Before the open | -1.40 | -0.29 | +79.5% |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.42 | — |
| Sep 17, 2020 | Before the open | -1.60 | -0.40 | +74.7% |
| Apr 16, 2020 | Before the open | -32.00 | -0.31 | +99.0% |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.30 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.43 | — |
| Aug 15, 2019 | Before the open | -32.00 | -0.42 | +98.7% |
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The…
| Mar 14, 2019 | Before the open | -2.22 | -0.62 | +72.0% |
| Nov 15, 2018 | Before the open | -43.75 | -56.00 | -28.0% |
| Aug 15, 2018 | Before the open | — | -10.21 | — |
| May 15, 2018 | Before the open | — | -0.30 | — |
| Mar 22, 2018 | Before the open | -714.53 | -0.97 | +99.9% |